Last reviewed · How we verify
Drug-induced coagulation inhibitor disorder
Approved treatments
- Praxbind · Boehringer Ingelheim
Idarucizumab reverses dabigatran's anticoagulant effect by binding to it and its metabolites with high affinity.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Drug-induced coagulation inhibitor disorder patent landscape — cliff calendar, originator estates, attackable patents
- Drug-induced coagulation inhibitor disorder treatment landscape brief
- Drug-induced coagulation inhibitor disorder treatment updates RSS
Frequently asked questions about Drug-induced coagulation inhibitor disorder
What drugs treat Drug-induced coagulation inhibitor disorder?
Tracked treatments include Praxbind.
What is the treatment for Drug-induced coagulation inhibitor disorder?
Standard treatment for Drug-induced coagulation inhibitor disorder includes Praxbind. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Drug-induced coagulation inhibitor disorder patent cliff · Drug-induced coagulation inhibitor disorder CI report
- Treatment: Praxbind · Boehringer Ingelheim
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing